Lapatinib no tratamento do câncer de mama avançado ou metastático

revisão sistemática

Autores

  • Rachel Riera Centro Paulista de Economia da Saúde , Universidade Federal de São Paulo
  • Patrícia Coelho de Soárez Centro Paulista de Economia da Saúde, Universidade Federal de São Paulo
  • Maria Eduarda dos Santos Puga Centro Paulista de Economia da Saúde, Universidade Federal de São Paulo
  • Marcos Bosi Ferraz Centro Paulista de Economia da Saúde, Universidade Federal de São Paulo

Palavras-chave:

Neoplasias de mama, Revisão, Antineoplásicos, Protocolos antineoplásicos, Receptor erbB-2

Resumo

CONTEXTO E OBJETIVO: Aproximadamente 16% a 20% das mulheres com câncer de mama têm doença avançada com metástases. Neste estágio, a doença é tratável, porém incurável. O objetivo foi avaliar a efetividade do lapatinib no tratamento de pacientes com câncer de mama avançado ou metastático. TIPO DE ESTUDO E LOCAL: Revisão sistemática da literatura desenvolvida no Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São Paulo (Unifesp). MÉTODO: Revisão sistemática com busca em bases de dados virtuais (PubMed, Lilacs [Literatura Latino-Americana e do Caribe em Ciências da Saúde], Cochrane Library, Scirus and Web of Science) e busca manual. RESULTADOS: Foi encontrado apenas um ensaio clínico que preencheu os critérios de seleção. Este estudo mostrou que o lapatinib em associação com a capecitabina reduziu em 51% o risco de progressão da doença (intervalo de confiança, IC 95%: 0,34-0,71; P < 0,001) quando comparado com a capecitabina isolada, sem aumento de efeitos adversos graves. CONCLUSÃO: A combinação de lapatinib e capecitabina foi mais efetiva do que a capecitabina isolada na redução do risco de progressão da doença. Ensaios clínicos aleatórios devem ser realizados com o objetivo de avaliar a efetividade do lapatinib como monoterapia ou em associação no tratamento primário ou secundário do câncer de mama avançado.

Downloads

Não há dados estatísticos.

Biografia do Autor

Rachel Riera, Centro Paulista de Economia da Saúde , Universidade Federal de São Paulo

MD, MSc. Physician and research assistant at Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil.

Patrícia Coelho de Soárez, Centro Paulista de Economia da Saúde, Universidade Federal de São Paulo

MSc. Dental surgeon, professor and researcher at Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil.

Maria Eduarda dos Santos Puga, Centro Paulista de Economia da Saúde, Universidade Federal de São Paulo

MSc. Librarian and research assistant at Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil.

Marcos Bosi Ferraz, Centro Paulista de Economia da Saúde, Universidade Federal de São Paulo

MD, MSc, PhD. Physician and Director of Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil.

Referências

Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl 8):S4-66.

Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus com- bination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;(2):CD003372.

New and Emerging Technology Briefing. National Horizon Scanning Centre. Lapatinib (GW572016) for advanced or metastatic breast cancer. The University of Birmingham; 2005. Available from: http://www.haps.bham.ac.uk/publichealth/horizon/outputs/documents/2005/Lapatinib.pdf. Accessed in 2009 (Oct 28).

National Institute for Clinical Excellence. Guidance on the use of trastuzumab for the treat- ment of advanced breast cancer. London: National Institute for Clinical Excellence; 2002. Available from: http://www.nice.org.uk/nicemedia/pdf/advancedbreastcancerno34PDF.pdf. Accessed in 2009 (Oct 28).

Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000;26(3): 151-68.

Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006;11(10):1047-57.

Johnston S, Stebbing J. Breast cancer: metastatic in clinical evidence, issue 8. London: BMJ Publishing Group; 2002.

Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003;(2):cd002747.

Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Semin Oncol. 1996;23(5 Suppl 11):1-5.

National Horizon Scanning Centre. New and Emerging Technology Briefing. Lapatinib (GW572016) for advanced or metastatic breast cancer. Available from: http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/496451/?query=GW572016&rank=100. Accessed in 2009 (Oct 28).

National Institute for Clinical Excellence. Guidance on the use of capecitabine for the treat- ment of locally advanced or metastatic breast cancer. Technology Appraisal

Available from: http://guidance.nice.org.uk/TA62. Accessed in 2009 (Nov12).

National Institute for Clinical Excellence. Guidance on the use of vinorelbine for the treatment of advanced breast cancer. London: National Institute for Clinical Excellence; 2002. Available from: http://www.burypct.nhs.uk/cg/nicepdf/niceta54.pdf. Accessed in 2009 (Oct 28).

National Institute for Clinical Excellence. Taxanes for the treatment of breast cancer. NICE Technology Appraisal Guidance. Available from: http://www.nice.org.uk/cat.asp?c=1122. Accessed in 2009 (Nov 12).

National Institute for Health and Clinical Excellence. Gemcitabine for the treatment of me- tastatic breast cancer. London: National Institute for Health and Clinical Excellence 2007. Available from: http://www.nice.org.uk/nicemedia/pdf/TA116guidance.doc. Accessed in 2009 (Oct 28).

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235(4785):177-82.

Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advan- ced breast cancer. N Engl J Med. 2006;355(26):2733-43.

Atalay G, Cardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epider- mal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol. 2003;14(9):1346-63.

Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estro- gen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005;65(1):18-25.

Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2000;37(Suppl 4):S3-8.

Rini BI. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist. 2005;10(3): 191-7.

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37.

Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21(14):2787-99.

Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/ EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001;61(19): 7196-203.

Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by he- regulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ ErbB2 kinase inhibitor GW572016. Oncogene. 2004;23(3):646-53.

Sáez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res. 2006;12(2):424-31.

Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22(6):1063-70.

Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advan- ced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006;11(4): 318-24.

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal anti- body against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.

Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-26.

Drugs for breast cancer. Treat Guidel Med Lett. 2005;3(29):1-6.

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.

Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4. Chichester: John Wiley & Sons Ltd; 2006. Available from: http://www.cochrane.org/resources/handbook/Handbook4.2.6Sep2006.pdf. Accessed in 2009 (Oct 27).

Geyer CE, Forster JK, Cameron D, et al. Scientific Special Session: Lapatinib in Trastuzumab Resistant Breast Cancer. In 42nd Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006; Atlanta. Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_de-tail_view&confID=40&abstractID=90002. Accessed in 2009 (Nov 16).

Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-43.

Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine Levels of Evi- dence (May 2001). Available from: http://www.cebm.net/index.aspx?o=1047. Accessed in 2009 (Nov 12).

Food and Drug Administration. FDA Approves Tykerb for Advanced Breast Cancer Patients. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108866.htm. Accessed in 2009 (Oct 28).

Gomez HL, Chavez MA, Doval DC, et al. A phase II, randomized trial using the small mo- lecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Journal of Clinical Oncology. 2005;23(16 Suppl 1). [abstract 3046]. Available from: http://www.cancer.net/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=31998. Accessed in 2009 (Oct 28).

ClinicalTrials.gov. Paclitaxel with/without GW572016 (lapatinib) as first line therapy for wo- men with advanced or metastatic breast cancer. Available from: http://www.clinicaltrials. gov/ct/show/NCT00075270?order=1. Accessed in 2009 (Oct 28).

ClinicalTrials.gov. ErbB2 over-expressing metastatic breast cancer study using paclita- xel, trastuzumab, and lapatinib. Available from: http://www.clinicaltrials.gov/ct/show/NCT00272987. Accessed in 2009 (Oct 29).

ClinicalTrials.gov . Study comparing GW572016 and letrozole versus letrozole in subjects with advanced or metastatic breast cancer. Available from: http://www.clinicaltrials.gov/ct/show/NCT00073528. Accessed in 2009 (Oct 29).

Paoletti P. SVP MDC oncology. Tikerb at ASCO 2006. Available from: http://www.gsk.com/investors/presentations/2006/06072006-roundtable-paole.pdf. Accessed in 2009 (Nov 12).

Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Journal of Cli- nical Oncology. 2004;22(14 Suppl.):196. [abstract 3006]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/3006. Accessed in 2009 (Oct 29).

Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. Journal of Clinical Oncology. 2005;23(Suppl 16):S193. [abstract 3004]. Available from: http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/3004?maxtoshow=&HITS=20&hits=20&RESULTFORMAT=&fulltext=Determining+relevant+biomarkers+from+tissue+and+serum+that+may+predict+response+to+single+agent+lapatinib+in+trastuzumab+refractory+metastatic+breast+cancer+&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT. Accessed in 2009 (Oct 29).

Burstein H, Storniolo AM, Franco S, et al. A phase II, open-label, multicenter study of la- patinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol. 2004;15(Suppl 3):iii27 (abstract 1040). Available from: http://annonc.oxfordjournals.org/cgi/reprint/15/suppl_3/iii27. Accessed in 2009 (Oct 29).

Lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with metastatic breast cancer. ClinicalTrials.gov [Web site]. Available from: http://www.clinical-trials.gov/ct/show/NCT00320385?order=1. Accessed in 2009 (Apr 16).

Lin NU, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT) [abstract]. Journal of Clinical Oncology. 2007;25(Suppl 18):S1012. Available from: http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/1012. Accessed in 2009 (Oct 28).

Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. Journal of Clinical Oncology. 2006;24(Suppl 18):S503. Available from: http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/503?maxtoshow=&HITS=20&hits=20&RESULTFORMAT=&fulltext=Phase+II+trial+of+lapatinib+for+brain+metastases+in+patients+with+HER2_breast+cancer&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT. Accessed in 2009 (Oct 28).

Trudeau M, Johnston S, Kaufman, et al. Lapatinib (Tykerb®) monotherapy in patients (PTS) with recurrent inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Annals of Oncology. 2006;17(Supplement. 9):ix69. Available from: http://annonc.oxfordjournals.org/cgi/reprint/17/suppl_9/ix69?ijkey=ef1d5135af012af5c4251bfec1ac99e8573ec9f9&keytype2=tf_ipsecsha. Accessed in 2009 (Oct 28).

Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [abstract]. Breast Cancer Research and Treatment. 2006;100(Suppl 1):S5.

Piccart-Gebhart MJ, Perez EA, Baselga J. ALTTO (adjuvant lapatinib and/or trastuzumab tre- atment optimization) study (BIG 2– 06/N063D/EGF106708): A phase III study for HER-2- overexpressing early breast cancer [abstract]. The Breast. 2006;15(Suppl 1):S5.

Moy B, Maltzman JD, Goss PE. Phase II study of lapatinib after completion of adjuvant therapy in trastuzumab-naive women with ErbB2-overexpressing breast cancer. The Breast. 2007;16(Suppl 1):S47.

Moy B, Goss PE. TEACH: Tykerb evaluation after chemotherapy. Clin Breast Cancer. 2007;7(6):489-92.

ClinicalTrials.gov. Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimi- zation) Study. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00553358?term=lapatinib&type=Intr&cond=breast+cancer&intr=%22Paclitaxel%22&rank=15. Accessed in 2009 (Oct 29).

Downloads

Publicado

2009-09-09

Como Citar

1.
Riera R, Soárez PC de, Puga ME dos S, Ferraz MB. Lapatinib no tratamento do câncer de mama avançado ou metastático: revisão sistemática. Sao Paulo Med J [Internet]. 9º de setembro de 2009 [citado 15º de outubro de 2025];127(5):295-301. Disponível em: https://periodicosapm.emnuvens.com.br/spmj/article/view/1900

Edição

Seção

Systematic Review